Market Place
Sourcing Support
Sagimet Bio to Participate in Piper Sandler 36th Annual Conference
26 Nov 2024 //
GLOBENEWSWIRE
Sagimet Presents Denifanstat & FASN Inhibitor Data at AASLD 2024
18 Nov 2024 //
GLOBENEWSWIRE
Sagimet Biosciences Reports Q3 2024 Results & Corporate Updates
14 Nov 2024 //
GLOBENEWSWIRE
Sagimet to Attend UBS Global Healthcare Conference
07 Nov 2024 //
GLOBENEWSWIRE
Sagimet Completes End-of-Ph 2 Interactions with FDA for Denifanstat
29 Oct 2024 //
GLOBENEWSWIRE
Sagimet Bio Announces Presentations At AASLD Liver Meeting 2024
16 Oct 2024 //
GLOBENEWSWIRE
Sagimet Announces Publishes FASCINATE-2 of Denifanstat Results In Lancet
11 Oct 2024 //
GLOBENEWSWIRE
Sagimet Receives FDA Breakthrough Designation for Denifanstat
01 Oct 2024 //
GLOBENEWSWIRE
Sagimet Biosciences To Present At H.C. Wainwright MASH Conference
01 Oct 2024 //
GLOBENEWSWIRE
Sagimet To Present At 8th Annual MASH Drug Development Summit
12 Sep 2024 //
GLOBENEWSWIRE
Sagimet to Participate in Two Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Sagimet Biosciences Reports Q2 2024 Financial Results And Corporate Updates
14 Aug 2024 //
GLOBENEWSWIRE
Sagimet Appoints Two New Board Members
01 Aug 2024 //
GLOBENEWSWIRE
Sagimet Hosts Call On FASCINATE-2 Denifanstat Data In ITT, F3 Patients
10 Jun 2024 //
GLOBENEWSWIRE
Sagimet Presents ITT And F3 Data From Phase 2b FASCINATE-2 At EASL 2024
06 Jun 2024 //
GLOBENEWSWIRE
Sagimet To Host Investor Day On FASN Inhibition May 23
16 May 2024 //
GLOBENEWSWIRE
Sagimet Biosciences Reports Q1 2024 Financials, Corporate Updates
15 May 2024 //
GLOBENEWSWIRE
Sagimet Oral Data From FASCINATE-2 Study At EASL 2024
07 May 2024 //
GLOBENEWSWIRE
Sagimet Biosciences Appoints Thierry Chauche As CFO
06 May 2024 //
GLOBENEWSWIRE
Sagimet FASN Liver Investor Day May 3
22 Apr 2024 //
GLOBENEWSWIRE
Sagimet Announces Completion of Phase 1 Study with FASN Inhibitor Denifanstat
27 Mar 2024 //
GLOBENEWSWIRE
Sagimet Reports Full Year 2023 Financial Results and Provides Corporate Updates
25 Mar 2024 //
GLOBENEWSWIRE
Sagimet Announces Appointment of Tim Walbert and Paul Hoelscher to its BOD
25 Mar 2024 //
GLOBENEWSWIRE
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
29 Feb 2024 //
PRESS RELEASE
Sagimet Bio Announces Pricing of Public Offering of Series A Common Stock
25 Jan 2024 //
GLOBENEWSWIRE
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
23 Jan 2024 //
GLOBENEWSWIRE
Sagimet stock doubles as phase 2b MASH trial hits primary goals
22 Jan 2024 //
FIERCE BIOTECH
Sagimet to Participate in the First Annual Goldman Sachs Catalyst Clinic
04 Dec 2023 //
GLOBENEWSWIRE
Sagimet`s NASH drug-GLP-1 combo tops either alone for fibrosis
30 Nov 2023 //
FIERCE BIOTECH
Sagimet Bio to Present at the 35th Annual Piper Sandler Healthcare Conference
22 Nov 2023 //
GLOBENEWSWIRE
Sagimet Biosciences Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Sagimet Presents Results Supporting Therapeutic Potential of its FASN inhibitor
10 Nov 2023 //
GLOBENEWSWIRE
Sagimet Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
24 Oct 2023 //
GLOBENEWSWIRE
Sagimet To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
18 Oct 2023 //
GLOBENEWSWIRE
Sagimet Announces Completion of Enrollment of 120 Patients for Phase 3 Trial
27 Sep 2023 //
GLOBENEWSWIRE
Sagimet Biosciences Reports Second Quarter 2023 Financial Results
21 Aug 2023 //
GLOBENEWSWIRE
Sagimet Announces Closing of Underwriters Option to Purchase Shares of Series A
15 Aug 2023 //
GLOBENEWSWIRE
Sagimet Biosciences Announces Leadership Changes
20 Jul 2023 //
GLOBENEWSWIRE
Apogee and Sagimet help crack open a stuck window on Wall Street
13 Jul 2023 //
ENDPTS
Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering
13 Jul 2023 //
GLOBENEWSWIRE
Apogee and Sagimet’s IPO plans come into view, with targeted raises of $228M
10 Jul 2023 //
ENDPTS
Sagimet Biosciences files again for an IPO after releasing NASH data
26 Jun 2023 //
ENDPTS
Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial
23 Jun 2023 //
GLOBENEWSWIRE
Sagimet to Present Data from Ph2b Trial of Denifanstat in NASH at EASL 2023
07 Jun 2023 //
GLOBENEWSWIRE
Sagimet Biosciences Announces Positive Phase 2b Trial Data with Denifanstat
03 Nov 2022 //
BUSINESSWIRE
Sagimet Announces Late-Breaking, Oral and Poster Presentations for Denifanstat
31 Oct 2022 //
BUSINESSWIRE
Sagimet Announces Appointment of David Happel to Chief Executive Officer
24 Oct 2022 //
BUSINESSWIRE
Sagimet Announces Completion of Patient Enrollment in P2b Trial with TVB-2640
13 Sep 2022 //
BUSINESSWIRE
Sagimet Bio Announces Oral Presentation on Denifanstat in NASH
04 Aug 2022 //
BUSINESSWIRE
Sagimet Biosciences Announces Presentation of Additional PII Data on Denifanstat
08 Jun 2022 //
BUSINESSWIRE
Sagimet to Present Additional Biomarker PII Data on Denifanstat
04 May 2022 //
BUSINESSWIRE
Published Sagimet`s FASN Inhibitor TVB-2640`s Significantly Reduc Liver Fat
26 Jul 2021 //
PRNEWSWIRE
Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640
23 Apr 2021 //
PRESS RELEASE
Sagimet Biosciences Receives Fast Track Designation from USFDA
16 Mar 2021 //
BIOSPACE
Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug
16 Mar 2021 //
PRNEWSWIRE
Sagimet Biosciences Names Dr. Eduardo Bruno Martins as Chief Medical Officer
11 Mar 2021 //
PRNEWSWIRE
ASC40 Shows Positive Ph2 Clinical Results from China Cohort of Patients
08 Mar 2021 //
PRNEWSWIRE
Sagimet Biosciences Raises $80 Million in Crossover Financing
11 Feb 2021 //
PRNEWSWIRE
